A subsidiary of POINT Biopharma Global (NASDAQ:PNT) signed an agreement for the supply of Actinium-225 (non-carrier-added Ac-225) from Eckert & Ziegler Strahlen EUZ (ETR) of Germany for POINT’s pipeline of next generation Ac-225-based radioligands.
Actinium-225 is used in cancer treatment, combining with a suitable carrier, such as an antibody or peptide, that specifically binds to cancer cells, selectively targeting them.
Clinical experts expect the demand for Actinium-225 to increase exponentially over the next decade. Eckert & Ziegler is currently developing a production process to be capable of supplying significant amounts of the highly demanded radionuclide Ac-225 to the market.
“As access to Actinium-225 is still very limited, we are happy to substantially improve this situation,” Dr. Harald Hasselmann, executive director and responsible for the medical segment of Eckert & Ziegler, said in a statement.
“With our own production, we will become one of the first commercial suppliers to make the radioisotope available globally,” he added.
Joe McCann, Ph.D., CEO of POINT, said the company anticipates launching its first Ac-225 Phase 1 trial for the next generation prostate-specific membrane antigen-targeted PNT2001 program later this year.
